Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 11 256 M
EBIT 2016 3 323 M
Net income 2016 1 709 M
Debt 2016 9 744 M
Yield 2016 -
Sales 2017 13 312 M
EBIT 2017 4 131 M
Net income 2017 2 561 M
Debt 2017 9 777 M
Yield 2017 -
P/E ratio 2016 15,06
P/E ratio 2017 10,53
EV / Sales2016 2,92x
EV / Sales2017 2,47x
Capitalization 23 119 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceutical products.It operates through two segments: Generic and Specialty.The Generic pharmaceutical business is conducted primarily in the U.S. and... 
Sector
Pharmaceuticals
Calendar
10/27Earnings Release
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN INC
08/29 Mylan to launch generic EpiPen at half the price of original
08/29 MYLAN : to Launch First Generic to EpiPen® Auto-Injector at a List Price of $300..
08/25 MYLAN : Taking Immediate Action to Further Enhance Access to EpiPen® (Epinephrin..
08/25DJMylan Boosts Price Assistance for EpiPen Amid Backlash
08/24 MYLAN : Invalidates Two of Teva's Copaxone® 40 mg/mL Patents Via U.S. Patent and..
08/09 MYLAN NV : second-quarter profit edges higher; EPS forecast unchanged
08/09 MYLAN NV : Reports Strong Second Quarter 2016 Results Including Total Revenues U..
08/09DJMylan Backs Year View After Sales Rise 8%
08/05 MYLAN NV : Completes Acquisition of Meda
08/04 Business groups sue over new U.S. limit on tax-driven foreign buyouts
More news
Sector news : Pharmaceuticals - NEC
10:01aDJOrexigen in Canadian Marketing Pact With Valeant for Diet Drug
02:49aDJBusiness Watch -- WSJ
08/29 Mylan to launch generic EpiPen at half the price of original
08/29DJMondelez Walks Away After Hershey Spurns Raised Bid
08/29DJROCHE : Receives US FDA Emergency Use Authorization for Zika Test -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Advertisement
Chart MYLAN INC
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 58,1 $
Spread / Average Target 34%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC-1.66%23 119
JOHNSON & JOHNSON16.74%328 086
PFIZER INC.8.77%212 965
ROCHE HOLDING LTD.-12.84%212 954
NOVARTIS AG-10.83%208 887
MERCK & CO., INC.19.29%174 236
More Results